• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Washington University School of Medicine

    Washington University School of Medicine

    院校
    4,441论文总数
    21.1万引用总数

    Washington University School of Medicine (WUSM) is the medical school of Washington University in St. Louis in St. Louis, Missouri. Founded in 1891, the School of Medicine has 1,260 students, 604 of which are pursuing a medical degree with or without a combined Doctor of Philosophy or other advanced degree. It also offers doctorate degrees in biomedical research through the Division of Biology and Biological Sciences. The School has developed large physical therapy (273 students) and occupational therapy (233 students) programs, as well as the Program in Audiology and Communication Sciences (100 students) which includes a Doctor of Audiology (Au.D.) degree and a Master of Science in Deaf Education (M.S.D.E.) degree. There are 1,772 faculty, 1,022 residents, and 765 fellows.The clinical service is provided by Washington University Physicians, a comprehensive medical and surgical practice providing treatment in more than 75 medical specialties. Washington University Physicians are the medical staffs of the two teaching hospitals – Barnes-Jewish Hospital and St. Louis Children's Hospital. They also provide inpatient and outpatient care at the St. Louis Veteran's Administration Hospital, hospitals in the BJC HealthCare system and 35 other office locations throughout the greater St Louis region. U.S. News and World Report ranks the college high; the school is currently ranked 6th for research and has been ranked as high as 2nd in 2003 and 2004, It has been listed among the top ten medical schools since rankings were first published in 1987. The school ranks first in the nation in student selectivity. As of 2019, it also receives the third most funding among all medical schools in the US from the National Institue of Health, totalling an amount of $218 million. Globally, the school is ranked as the 20th and 35th best medical program in 2020 by the Times Higher Education’s World University Rankings for medicine and QS World University Ranking for medicine, respectively.

    论文量&引用量时间轴

    机构学者

    论文(4442)

    年份
    起
    –
    止
    排序
    1Adapting Medical Vision Foundation Models for Volumetric Medical Image Segmentation Via Active Learning and Selective Semi-supervised Fine-tuning
    Jin Yang,Daniel S. Marcus,Aristeidis Sotiras

    Medical vision foundation models (Med-VFMs) have shown strong potential for medical image analysis by leveraging representations learned from large-scale self-supervised pre-training on unlabeled data. However, their performance and generalization remain limited in downstream tasks, particularly volumetric medical image segmentation. Although fine-tuning on labeled target-domain data improves performance, existing approaches typically rely on randomly selected samples, which may overlook informative data and hinder adaptation. To address this, we propose an Active Selective Semi-supervised Fine-tuning (ASSFT) framework for efficient adaptation of Med-VFMs to volumetric segmentation tasks. ASSFT integrates active learning with selective semi-supervised learning to maximize performance under limited annotation budgets without requiring source data. Specifically, we introduce an Active Test-Time Sample Query strategy that identifies informative target-domain samples using two complementary metrics: Diversified Knowledge Divergence (DKD) and Anatomical Segmentation Difficulty (ASD). DKD captures both the knowledge gap between pre-training and target domains and intra-domain diversity, enabling selection of samples containing novel and diverse information. ASD estimates segmentation difficulty by measuring predictive uncertainty in foreground regions, prioritizing anatomically complex cases over background-dominated samples. Furthermore, we propose a Selective Semi-supervised Fine-tuning strategy that leverages unlabeled data by incorporating only reliable pseudo-labeled samples based on predictive confidence and semantic proximity to labeled data, thereby mitigating noise. Extensive experiments on five volumetric segmentation tasks demonstrate that ASSFT consistently outperforms state-of-the-art active learning and domain adaptation methods while requiring substantially fewer annotations, highlighting its effectiveness, efficiency, and strong generalization capability.

    2027PATTERN RECOGNITION(2027)
    引用
    AI阅读
    加入学术空间
    2Developing a Core Outcome Set for the NeuroPoint Alliance Quality Outcomes Database Pediatric Tumor Surgery Registry: a Modified Delphi Study.
    David S. Hersh,Anthony L. Asher, Mohamad Bydon, Maliya Delawan,Ian F. Pollack, Jason S. Hauptman, Eric M. Thompson,Michael C. Dewan,S. Hassan. A. Akbari, Karl Balsara, Randaline R. Barnett, Marian M. Bercu,

    Prospective, multi-institutional surgical data collection in pediatric neuro-oncology remains limited despite substantial variation in operative and perioperative management across institutions. To address this, we are developing the NeuroPoint Alliance (NPA) Quality Outcomes Database (QOD) Pediatric Tumor Surgery Registry. Here, we used a modified Delphi process to define a core outcome set for the registry. A modified Delphi study was conducted among pediatric neurosurgeons serving as site principal investigators for the proposed registry. Candidate data elements were rated on a 9-point Likert scale. Consensus for inclusion was predefined as ≥70

    2026Journal of Neuro-Oncology(2026)引用:28
    引用
    AI阅读
    加入学术空间
    3Concordance of Large Language Model Recommendations with Multidisciplinary Heart Team Decisions in Coronary Revascularization and Aortic Valve Intervention: A Systematic Review and Pooled Analysis.
    Armaun D. Rouhi, Shreyas V. Menon, Yazid K. Ghanem,Jason J. Han

    The multidisciplinary heart team (HT) remains the cornerstone of decision-making for complex cardiovascular disease. Large language models (LLMs) and other generative artificial intelligence models have recently emerged as potential decision support tools across diverse clinical settings. We sought to synthesize current evidence and quantitatively estimate concordance between LLM recommendations and HT decisions. A literature search was performed using PubMed, Scopus, and Web of Science for primary studies published between November 2022 and February 2026 that evaluated recommendations by LLMs against multidisciplinary HT decisions. Studies reporting overall agreement were included for quantitative pooling. Random-effects meta-analysis was performed to determine proportion of agreement. Four retrospective concordance studies were included regarding decision-making in coronary revascularization and aortic valve intervention. LLM–HT concordance ranged from 65

    2026Cardiology and Therapy(2026)引用:22
    引用
    AI阅读
    加入学术空间
    4Antibodies to Watch in 2026
    Silvia Crescioli,Hélène Kaplon, Alicia Chenoweth, Yu-Shin Hsu, Kieran Pinto,Vaishali Kapoor, Janice M Reichert

    The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics. Since the first article was published in 2010, the late-stage pipeline has grown from 26 antibody therapeutics to over 200, while during the same time numerous molecules in late-stage studies either transitioned to regulatory review and were approved or were terminated. In this installment of the series, we recap first marketing approvals granted to 19 antibody therapeutics in 2025, discuss 26 molecules currently in regulatory review, including the bispecific antibody-drug conjugate izalontamab brengitecan, and predict which molecules of the 209 currently in the commercial late-stage pipeline might transition to regulatory review by the end of 2026. Most antibody therapeutics in the latter category are for non-cancer indications (16/21, 76%) and have a conventional format (13/21, 62%), but the category also includes numerous antibody-oligo or -drug conjugates, such as delpacibart etedesiran, delpacibart zotadirsen, zeleciment rostudirsen, sonesitatug vedotin, trastuzumab pamirtecan, and ifinatamab deruxtecan, as well as the bispecific petosemtamab. As antibody therapeutics development is a global enterprise, we also discuss trends in annual first approvals granted to antibody therapeutics in any country since 2010, stratified by the antibody's country of origin, documenting the notable increases in the total number of first approvals and those approved first in China. Finally, to benchmark the time typically required for clinical development and regulatory review, we calculated this period for recently approved antibody therapeutic products stratified by their therapeutic area, mechanism of action, format, and country of origin. Our data show that the development and approval period were typically ~6 years, but on average this period was shorter for China-originated products.

    2026mAbs(2026)引用:10
    引用
    AI阅读
    加入学术空间
    5Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    Hiddo J L Heerspink,Andreas L Birkenfeld, David Z I Cherney, Helen M Colhoun,Per-Henrik Groop,Linong Ji,Niels Jongs,Chantal Mathieu,Richard E Pratley,Sylvia E Rosas,Peter Rossing, Jay S Skyler,

    BACKGROUND:The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown. METHODS:We conducted a phase 3 trial involving adults who had type 1 diabetes, CKD (estimated glomerular filtration rate [eGFR], 25 to <90 ml per minute per 1.73 m2 of body-surface area), and albuminuria (urinary albumin-to-creatinine ratio [with albumin measured in milligrams and creatinine measured in grams], 200 to <5000) and were receiving an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin-receptor blocker. Participants were randomly assigned to receive finerenone (10 or 20 mg per day, depending on the eGFR) or matching placebo. The primary outcome was the relative change in the urinary albumin-to-creatinine ratio over a period of 6 months. RESULTS:A total of 242 participants underwent randomization. The median urinary albumin-to-creatinine ratio decreased from 574.6 at baseline to 373.5 at 6 months among all the participants assigned to receive finerenone and from 506.4 to 475.6 among those assigned to receive placebo. Over a period of 6 months, the urinary albumin-to-creatinine ratio decreased by 34% with finerenone (geometric mean ratio to baseline, 0.66; 95% confidence interval [CI], 0.60 to 0.73) and 12% with placebo (geometric mean ratio to baseline, 0.88; 95% CI, 0.79 to 0.98), which corresponded to a 25% greater reduction with finerenone than with placebo (geometric mean ratio for finerenone vs. placebo, 0.75; 95% CI, 0.65 to 0.87; P<0.001). The most common adverse event was hyperkalemia (in 12 participants [10.1%] with finerenone and in 4 [3.3%] with placebo); 2 participants (1.7%) discontinued finerenone because of hyperkalemia. At 6 months, the change in the eGFR was -5.6 ml per minute per 1.73 m2 with finerenone and -2.7 ml per minute per 1.73 m2 with placebo (difference, -2.9 ml per minute per 1.73 m2; 95% CI, -5.1 to -0.7); eGFR values approached baseline levels during the washout period. CONCLUSIONS:In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).

    2026The New England journal of medicine(2026)引用:9
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4442 篇论文

    合作机构(100)

    华盛顿大学合作论文 881
    圣路易斯华盛顿大学合作论文 481
    University of Washington School of Medicine合作论文 301
    加州大学合作论文 132
    温纳贝戈医学中心合作论文 123
    Massachusetts General Hospital,Harvard Medical School合作论文 113
    密歇根大学合作论文 100
    哈佛医学院合作论文 97
    哥伦比亚大学合作论文 96
    纪念斯隆凯特琳癌症中心合作论文 92

    机构统计